| Recruiting | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC) | Phase 3 | 2026-03-25 |
| Recruiting | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent G Neoplastic Disease, Glioblastoma, Glioblastoma (GBM) | Phase 3 | 2025-11-02 |
| Recruiting | Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer | Phase 1 | 2025-10-21 |
| Active Not Recruiting | [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes Retrospective Study, Glioma, Brain Neoplasms | — | 2025-09-22 |
| Recruiting | PSMA PET Combined With MRI for the Detection of PCa PCA, Prostate Cancer, Prostatic Neoplasm | Phase 3 | 2025-08-18 |
| Terminated | Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations Prostate Cancer (Adenocarcinoma) | — | 2025-01-30 |
| Recruiting | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study Clear Cell Renal Cell Carcinoma | Phase 3 | 2024-11-06 |
| Recruiting | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) Metastatic Castration-resistant Prostate Cancer | Phase 3 | 2024-07-26 |
| Recruiting | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | Phase 3 | 2023-07-19 |
| Completed | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Re Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1 | 2023-06-26 |
| Recruiting | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma | Phase 1 | 2023-05-23 |
| Recruiting | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme | Phase 1 | 2023-04-01 |
| Completed | External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGE Prostate Cancer | Phase 2 | 2022-08-30 |
| Completed | 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study Metastatic Prostate Cancer | Phase 1 | 2022-01-30 |
| Completed | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) Metastatic Prostate Cancer | EARLY_Phase 1 | 2021-08-04 |
| Completed | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subject Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma | Phase 1 | 2020-08-01 |
| Completed | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study Clear Cell Renal Cell Carcinoma | Phase 3 | 2019-08-15 |
| Completed | 131I-IPA and Concurrent XRT in Recurrent GBM Glioblastoma Multiforme | Phase 1 / Phase 2 | 2019-04-09 |
| Available | 89Zr-DFO-girentuximab Expanded Access Program (EAP) Clear Cell Renal Cell Carcinoma | — | — |
| Available | 18F-Floretyrosine Expanded Access Program Glioma (Any Grade) in the Brain | — | — |